Latest International Expansion News

Pure One Corporation Limited (ASX:P1E) reported FY26 net profit after tax of A$5.070 million, alongside A$7.191 million in cash and term deposits. The company is positioning battery-swappable heavy vehicles and electric vans as its growth engine, while retaining sizeable interests in gas and clean-energy ventures.

Felix Group Holdings grew FY26 revenue and contracted ARR after acquiring Nexvia, but operating losses and cash outflows widened sharply. The ASX-listed software company is now relying on a post-year-end capital raising while it narrows its strategy to Australia and New Zealand.

Cann Group’s FY2026 profit was transformed by a one-off A$55.7 million debt-forgiveness gain, while a leaner cost base and new export sales offered more durable progress. The company remains loss-making on a normalised basis and dependent on lender waivers and a future refinancing.

Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.

Viva Leisure used FY2026 to prove its existing club network could generate stronger returns without rapid expansion, lifting revenue 12.2% and underlying NPAT 46.4%. The ASX-listed fitness group is now preparing to accelerate openings while reviewing options for its faster-growing payments and technology business.

Rubicon Water’s technology has been selected as part of a joint venture bid for a major Moroccan irrigation upgrade covering 69,600 hectares. The opportunity could become its largest EMEA contract, but formal execution remains subject to a 15-day appeal period and subsequent commissioning.

SkinKandy Limited (ASX:SK1) exceeded its IPO forecasts in FY26, with pro forma revenue rising 29% to A$90.2 million and pro forma NPAT climbing 41% to A$9.0 million. The newly listed retailer enters FY27 with 115 stores, 11 approved leases and plans for potential expansion into South Africa and the United States.

Me Today reported a NZ$2.66 million FY26 profit, but the result was dominated by a NZ$4.12 million gain from losing control of King Honey. The remaining business grew revenue and improved its operating loss, yet continued to consume cash and will rely on October warrant funding.

Stakk says recurring contracts now support 100% of its approximately A$55.2 million FY2027 pro-forma revenue forecast, while fresh international wins are being built into the FY2028 growth story. The company will establish Singapore as its non-US commercial, service and technology hub from November 2026.

Biome Australia Limited (ASX:BIO) delivered its second consecutive profitable year in FY26, with revenue rising 30% to $23.9 million and operating cash flow turning positive. But the headline $3.6 million profit includes a $2.4 million deferred tax benefit, leaving FY27 execution as the real test of the company’s growth plan.

Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.

Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.